Skip to content

Study · Randomized controlled trial · n = 28 · 2016

2 results

Relationship of plasma oxytocin levels to baseline symptoms and symptom changes during three weeks of daily oxytocin administration in people with schizophrenia.

Lee MR, Wehring HJ, McMahon RP, Liu F, Linthicum J, Verbalis JG, Buchanan RW, Strauss GP, Rubin LH, Kelly DL

Schizophrenia research12 Feb 2016Cited by 17 (Europe PMC)

PMID26879587 (opens in a new tab)PMCIDPMC4821731 (opens in a new tab)DOI10.1016/j.schres.2016.02.014 (opens in a new tab)PepBankPUB-26879587
Source linkPubMedAsk about this study
Jump to 2 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study2

2 results from studies that gave the peptide. 2 results from people.

  1. 01HumanRandomized controlled trialPharmacokinetics

    In patients with schizophrenia, 3 weeks of intranasal oxytocin did not change peripheral oxytocin levels differently from placebo.

    In plain wordsIn people with schizophrenia, 3 weeks of nasal oxytocin did not change blood oxytocin levels more than placebo did.

    Peptide
    Oxytocin
    Outcome
    No significant changeChange in peripheral oxytocin levels after 3 weeks
    Study

    n = 28

    Comparator
    Placebo
    Outcome group
    Pharmacokinetics · Pharmacology
    Studied dose
    20 IU twice daily · intranasal · 3 weeksAs given in this study (human).

    Source sentences

    Summary
    After 3 weeks of OT/PBO dosing, there was no significant difference in the magnitude of change in OT levels between the two treatment groups.
    1 context sentence
    Summary · context
    In a, randomized, double blind, parallel group 3 week study (N=28) with daily administration of intranasal OT (20 IU twice daily) or placebo (PBO), we examined the effect of OT administration on the correlation between the change in peripheral OT levels and change in clinical symptoms in patients with schizophrenia.
  2. 02HumanRandomized controlled trialMechanism

    In patients with schizophrenia, correlations between changes in peripheral oxytocin levels and changes in BPRS total and negative symptom scores did not differ between oxytocin and placebo groups.

    In plain wordsIn people with schizophrenia, the link between changes in blood oxytocin and changes in symptoms was not different with nasal oxytocin than with placebo.

    Peptide
    Oxytocin
    Outcome
    No significant changeCorrelation of change in oxytocin levels with change in BPRS total and negative symptom scores
    Study

    n = 28

    Comparator
    Placebo
    Outcome group
    Social behavior and cognition · Mental health and mood
    Studied dose
    20 IU twice daily · intranasal · 3 weeksAs given in this study (human).

    Source sentences

    Summary
    Correlations between changes in peripheral OT levels and changes in the BPRS total and negative symptom scores were not different between treatment groups.
    1 context sentence
    Summary · context
    In a, randomized, double blind, parallel group 3 week study (N=28) with daily administration of intranasal OT (20 IU twice daily) or placebo (PBO), we examined the effect of OT administration on the correlation between the change in peripheral OT levels and change in clinical symptoms in patients with schizophrenia.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials2

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

2 trials · 2 completed · 1 with posted results · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase 2NCT01699997

Oxytocin as Adjunctive Therapy for Schizophrenia

IRCCS Centro San Giovanni di Dio Fatebenefratellin = 32Jan 2014 to Nov 2015

Schizophrenia

Trial pageClinicalTrials.govUpdated 24 Feb 2016
CompletedPhase 2Results postedNCT00884897

Oxytocin and Social Cognition in Schizophrenia

University of Maryland, Baltimoren = 28Jan 2010 to Jan 2012

Social Cognition · Social Anxiety · Emotional Intelligence

Trial pageClinicalTrials.govUpdated 2 Oct 2019

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    11 Oct 2026, 01:30 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 02:49 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.